Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculations
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing incidence of cholera outbreaks.
3.2.1.2 Growing governments support
3.2.1.3 Expanding research funding and activities
3.2.1.4 Growing travel to endemic regions
3.2.2 Industry pitfalls & challenges
3.2.2.1 Lack of access to adequate treatment
3.2.2.2 Cold chain requirements
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Dukoral
5.3 Vaxchora
5.4 Euvichol/Euvichol-Plus
5.5 Other products
Chapter 6 Market Estimates and Forecast, By End-User, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Public
6.3 Private
Chapter 7 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.3 Europe
7.3.1 UK
7.3.2 France
7.3.3 Spain
7.3.4 Netherlands
7.3.5 Belgium
7.3.6 Croatia
7.3.7 Rest of Europe
7.4 Asia Pacific
7.4.1 India
7.4.2 Bangladesh
7.4.3 Pakistan
7.4.4 Philippines
7.4.5 Rest of Asia Pacific
7.5 Latin America
7.5.1 Columbia
7.5.2 Peru
7.5.3 Chile
7.5.4 Rest of Latin America
7.6 Middle East and Africa
7.6.1 Syria
7.6.2 Uganda
7.6.3 Yemen
7.6.4 Kenya
7.6.5 Zimbabwe
7.6.6 Rest of Middle East and Africa
Chapter 8 Company Profiles
8.1 Bavarian Nordic A/S
8.2 Bharat Biotech
8.3 Biological E
8.4 EuBiologics Co. Ltd.
8.5 Hilleman Laboratories
8.6 Incepta Pharmaceuticals Ltd.
8.7 Shantha Biotechnics (Sanofi)
8.8 Vabiotech
8.9 Valneva Sweden AB
